Minimal Residual Disease Clinical Trials

17 recruiting

Minimal Residual Disease Trials at a Glance

18 actively recruiting trials for minimal residual disease are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Beijing, Seattle, and New Orleans. Lead sponsors running minimal residual disease studies include Peking University People's Hospital, Caris Science, Inc., and Beijing 302 Hospital.

Browse minimal residual disease trials by phase

Treatments under study

About Minimal Residual Disease Clinical Trials

Looking for clinical trials for Minimal Residual Disease? There are currently 17 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Minimal Residual Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Minimal Residual Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 1Phase 2

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic LeukemiaMinimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Amgen104 enrolled4 locationsNCT07134088
Recruiting
Phase 2

A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Minimal Residual DiseaseAdjuvant Chemotherapy
M.D. Anderson Cancer Center20 enrolled1 locationNCT07136077
Recruiting
Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting

To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)

Neoadjuvant TherapyLung NeoplasmsMinimal Residual Disease+1 more
Peking University People's Hospital100 enrolled1 locationNCT07291921
Recruiting

Caris Biorepository Research Protocol

CancerMinimal Residual DiseaseEarly Detection of Cancer
Caris Science, Inc.100,000 enrolled38 locationsNCT01499394
Recruiting
Phase 1

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+26 more
Fred Hutchinson Cancer Center24 enrolled1 locationNCT03326921
Recruiting

French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC)

Pancreatic Ductal AdenocarcinomaMinimal Residual DiseasectDNA+2 more
University Hospital, Montpellier37 enrolled1 locationNCT06287749
Recruiting

Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil

Chemotherapeutic ToxicityMinimal Residual DiseaseGene Abnormality+1 more
Instituto do Cancer do Estado de São Paulo180 enrolled1 locationNCT05959720
Recruiting
Not Applicable

Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer

Non-small Cell Lung CancerMinimal Residual DiseaseAdaptive Treatment
Peking University People's Hospital1,000 enrolled1 locationNCT06930807
Recruiting
Not Applicable

Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients

Acute Myeloid LeukemiaMinimal Residual DiseaseNatural Killer Cell
IRCCS Azienda Ospedaliero-Universitaria di Bologna22 enrolled1 locationNCT06885476
Recruiting

CtDNA Based MRD Testing for NAC Monitoring in TNBC

TNBC - Triple-Negative Breast CancerMinimal Residual Disease
Personalis Inc.422 enrolled14 locationsNCT06230185
Recruiting

Better Leukemia Diagnostics Through AI (BELUGA)

LymphomaMinimal Residual DiseaseLeukemia+2 more
Munich Leukemia Laboratory25,000 enrolled1 locationNCT04466059
Recruiting
Phase 2

VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS

Minimal Residual DiseaseMyelodysplastic SyndromesRefractory Acute Myeloid Leukemia+1 more
Beijing 302 Hospital67 enrolled1 locationNCT06536959
Recruiting

A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment

Multiple MyelomaMinimal Residual Disease
FengYan Jin80 enrolled1 locationNCT06109233
Recruiting

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

Multiple MyelomaMinimal Residual Disease
First Affiliated Hospital of Zhejiang University210 enrolled1 locationNCT06463717
Recruiting
Not Applicable

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Minimal Residual DiseaseAML, Adult
Guangdong Provincial People's Hospital60 enrolled1 locationNCT06066905
Recruiting

Minimally Residual of Esophageal Cancer 001

Esophageal CarcinomaMinimal Residual Disease
Hebei Medical University Fourth Hospital56 enrolled1 locationNCT05952661
Recruiting

Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD

Minimal Residual DiseaseGastrointestinal Stromal Tumors
Peking University People's Hospital45 enrolled1 locationNCT05408897